Ethicon Seeks To Expand Access To Bariatric Surgery, Increase Product Market Share Through Investment
Executive Summary
With nearly 30% of the world’s population overweight or obese, Johnson & Johnson's Ethicon division is seeking to expand patients’ access to bariatric surgery in certain countries by funding studies that demonstrate its benefits. By convincing payors in these countries that bariatric surgery addresses not only weight loss but also metabolic diseases, Ethicon hopes to increase its products' market share in these countries, too.
You may also be interested in...
Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.